
The following have been reloaded with a version change:
  1) GCCcore/9.3.0 => GCCcore/8.3.0
  2) binutils/2.34-GCCcore-9.3.0 => binutils/2.32-GCCcore-8.3.0
  3) zlib/1.2.11-GCCcore-9.3.0 => zlib/1.2.11-GCCcore-8.3.0


The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-02-09 04:32:15 | INFO | fairseq_cli.train | Namespace(activation_dropout=0.0, activation_fn='relu', adam_betas='(0.9, 0.98)', adam_eps=1e-08, adaptive_input=False, adaptive_softmax_cutoff=None, adaptive_softmax_dropout=0, all_gather_list_size=16384, arch='transformer_vaswani_wmt_en_de_big', attention_dropout=0.0, best_checkpoint_metric='bleu', bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', clip_norm=0.0, cpu=False, criterion='label_smoothed_cross_entropy', cross_self_attention=False, curriculum=0, data='../../../data-bin/phrase4_0.5_tag_TP_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoder_attention_heads=16, decoder_embed_dim=1024, decoder_embed_path=None, decoder_ffn_embed_dim=4096, decoder_input_dim=1024, decoder_layerdrop=0, decoder_layers=6, decoder_layers_to_keep=None, decoder_learned_pos=False, decoder_normalize_before=False, decoder_output_dim=1024, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', dropout=0.2, empty_cache_freq=0, encoder_attention_heads=16, encoder_embed_dim=1024, encoder_embed_path=None, encoder_ffn_embed_dim=8192, encoder_layerdrop=0, encoder_layers=6, encoder_layers_to_keep=None, encoder_learned_pos=False, encoder_normalize_before=False, eval_bleu=True, eval_bleu_args='{"beam": 5, "max_len_a": 1.2, "max_len_b": 10}', eval_bleu_detok='moses', eval_bleu_detok_args=None, eval_bleu_print_samples=True, eval_bleu_remove_bpe='@@ ', eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, fixed_validation_seed=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, label_smoothing=0.1, layernorm_embedding=False, left_pad_source='True', left_pad_target='False', load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr=[5e-05], lr_scheduler='inverse_sqrt', max_epoch=10, max_sentences=None, max_sentences_valid=None, max_source_positions=1024, max_target_positions=1024, max_tokens=4096, max_tokens_valid=4096, max_update=0, maximize_best_checkpoint_metric=True, memory_efficient_bf16=False, memory_efficient_fp16=False, min_loss_scale=0.0001, min_lr=-1, model_parallel_size=1, no_cross_attention=False, no_epoch_checkpoints=True, no_last_checkpoints=False, no_progress_bar=False, no_save=False, no_save_optimizer_state=False, no_scale_embedding=False, no_seed_provided=True, no_token_positional_embeddings=False, nprocs_per_node=1, num_batch_buckets=0, num_workers=1, optimizer='adam', optimizer_overrides='{}', patience=-1, profile=False, quant_noise_pq=0, quant_noise_pq_block_size=8, quant_noise_scalar=0, quantization_config_path=None, required_batch_size_multiple=8, reset_dataloader=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=True, restore_file='../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt', save_dir='../checkpoints/EMEA_p_4_tp', save_interval=1, save_interval_updates=0, scoring='bleu', seed=1, sentence_avg=False, share_all_embeddings=False, share_decoder_input_output_embed=True, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, stop_time_hours=0, target_lang=None, task='translation', tensorboard_logdir='', threshold_loss_scale=None, tie_adaptive_weights=False, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, update_freq=[1], upsample_primary=1, use_bmuf=False, use_old_adam=False, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, warmup_init_lr=-1, warmup_updates=4000, weight_decay=0.0001)
2021-02-09 04:32:15 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-02-09 04:32:15 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-02-09 04:32:15 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase4_0.5_tag_TP_EMEA/valid.de-en.de
2021-02-09 04:32:15 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase4_0.5_tag_TP_EMEA/valid.de-en.en
2021-02-09 04:32:15 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_tag_TP_EMEA valid de-en 151 examples
2021-02-09 04:32:21 | INFO | fairseq_cli.train | TransformerModel(
  (encoder): TransformerEncoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
  )
  (decoder): TransformerDecoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
    (output_projection): Linear(in_features=1024, out_features=42024, bias=False)
  )
)
2021-02-09 04:32:21 | INFO | fairseq_cli.train | model transformer_vaswani_wmt_en_de_big, criterion LabelSmoothedCrossEntropyCriterion
2021-02-09 04:32:21 | INFO | fairseq_cli.train | num. model params: 312778752 (num. trained: 312778752)
2021-02-09 04:32:29 | INFO | fairseq.trainer | detected shared parameter: decoder.embed_tokens.weight <- decoder.output_projection.weight
2021-02-09 04:32:29 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-09 04:32:29 | INFO | fairseq.utils | rank   0: capabilities =  7.0  ; total memory = 32.000 GB ; name = GRID V100D-32Q                          
2021-02-09 04:32:29 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-09 04:32:29 | INFO | fairseq_cli.train | training on 1 devices (GPUs/TPUs)
2021-02-09 04:32:29 | INFO | fairseq_cli.train | max tokens per GPU = 4096 and max sentences per GPU = None
2021-02-09 04:32:36 | INFO | fairseq.trainer | loaded checkpoint ../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt (epoch 16 @ 0 updates)
2021-02-09 04:32:36 | INFO | fairseq.trainer | loading train data for epoch 1
2021-02-09 04:32:37 | INFO | fairseq.data.data_utils | loaded 93981 examples from: ../../../data-bin/phrase4_0.5_tag_TP_EMEA/train.de-en.de
2021-02-09 04:32:37 | INFO | fairseq.data.data_utils | loaded 93981 examples from: ../../../data-bin/phrase4_0.5_tag_TP_EMEA/train.de-en.en
2021-02-09 04:32:37 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_tag_TP_EMEA train de-en 93981 examples
2021-02-09 04:32:38 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-09 04:32:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 64.0
2021-02-09 04:32:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 32.0
2021-02-09 04:32:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 16.0
2021-02-09 04:32:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 8.0
2021-02-09 04:32:40 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 4.0
2021-02-09 04:32:40 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 2.0
2021-02-09 04:32:59 | INFO | train_inner | epoch 001:    106 / 208 loss=3.128, nll_loss=1.378, ppl=2.6, wps=19358.4, ups=5.16, wpb=3754.9, bsz=445.4, num_updates=100, lr=1.25e-06, gnorm=8.34, loss_scale=2, train_wall=19, wall=30
2021-02-09 04:33:18 | INFO | train_inner | epoch 001:    206 / 208 loss=2.876, nll_loss=1.098, ppl=2.14, wps=19329, ups=5.25, wpb=3683.3, bsz=454.5, num_updates=200, lr=2.5e-06, gnorm=2.761, loss_scale=2, train_wall=19, wall=49
2021-02-09 04:33:18 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:33:20 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:33:20 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:33:21 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used together with long acting insulin preparations.
2021-02-09 04:33:21 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:33:22 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood sugar control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-09 04:33:22 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:33:25 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two studies with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (one study with 182 patients). In the studies, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit did actrapid show in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-09 04:33:25 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:33:25 | INFO | valid | epoch 001 | valid on 'valid' subset | loss 3.899 | nll_loss 2.197 | ppl 4.58 | bleu 32.69 | wps 697 | wpb 1083 | bsz 37.8 | num_updates 202
2021-02-09 04:33:25 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:33:43 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 1 @ 202 updates, score 32.69) (writing took 17.513094464316964 seconds)
2021-02-09 04:33:43 | INFO | fairseq_cli.train | end of epoch 1 (average epoch stats below)
2021-02-09 04:33:43 | INFO | train | epoch 001 | loss 2.997 | nll_loss 1.232 | ppl 2.35 | wps 11905.8 | ups 3.2 | wpb 3721.9 | bsz 450.5 | num_updates 202 | lr 2.525e-06 | gnorm 5.507 | loss_scale 3 | train_wall 40 | wall 74
2021-02-09 04:33:43 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-09 04:34:01 | INFO | train_inner | epoch 002:     98 / 208 loss=2.701, nll_loss=0.912, ppl=1.88, wps=8544.3, ups=2.3, wpb=3707.3, bsz=455.8, num_updates=300, lr=3.75e-06, gnorm=1.812, loss_scale=2, train_wall=19, wall=93
2021-02-09 04:34:21 | INFO | train_inner | epoch 002:    198 / 208 loss=2.656, nll_loss=0.861, ppl=1.82, wps=19383.8, ups=5.21, wpb=3717.5, bsz=451.5, num_updates=400, lr=5e-06, gnorm=1.467, loss_scale=2, train_wall=19, wall=112
2021-02-09 04:34:23 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:34:23 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:34:23 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:34:24 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:34:24 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:34:25 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-09 04:34:25 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:34:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two studies with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a study with 182 patients). In the studies, Actrapid was compared to a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit has actrapid shown in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-09 04:34:28 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:34:28 | INFO | valid | epoch 002 | valid on 'valid' subset | loss 3.758 | nll_loss 2.033 | ppl 4.09 | bleu 35.97 | wps 735 | wpb 1083 | bsz 37.8 | num_updates 410 | best_bleu 35.97
2021-02-09 04:34:28 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:34:46 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 2 @ 410 updates, score 35.97) (writing took 18.0840239264071 seconds)
2021-02-09 04:34:46 | INFO | fairseq_cli.train | end of epoch 2 (average epoch stats below)
2021-02-09 04:34:46 | INFO | train | epoch 002 | loss 2.67 | nll_loss 0.877 | ppl 1.84 | wps 12163.3 | ups 3.27 | wpb 3719.9 | bsz 451.8 | num_updates 410 | lr 5.125e-06 | gnorm 1.616 | loss_scale 2 | train_wall 40 | wall 138
2021-02-09 04:34:46 | INFO | fairseq_cli.train | begin training epoch 2
2021-02-09 04:35:04 | INFO | train_inner | epoch 003:     90 / 208 loss=2.57, nll_loss=0.762, ppl=1.7, wps=8663.3, ups=2.33, wpb=3716.2, bsz=449.7, num_updates=500, lr=6.25e-06, gnorm=1.425, loss_scale=2, train_wall=19, wall=155
2021-02-09 04:35:23 | INFO | train_inner | epoch 003:    190 / 208 loss=2.503, nll_loss=0.687, ppl=1.61, wps=19530, ups=5.22, wpb=3741.5, bsz=460.6, num_updates=600, lr=7.5e-06, gnorm=1.274, loss_scale=2, train_wall=19, wall=174
2021-02-09 04:35:26 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:35:27 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:35:27 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:35:27 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:35:27 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:35:28 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy, which are usually reversible.
2021-02-09 04:35:28 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:35:31 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is regulated. What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with Actrapid.
2021-02-09 04:35:31 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:35:31 | INFO | valid | epoch 003 | valid on 'valid' subset | loss 3.68 | nll_loss 1.936 | ppl 3.83 | bleu 37.84 | wps 769 | wpb 1083 | bsz 37.8 | num_updates 618 | best_bleu 37.84
2021-02-09 04:35:31 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:35:49 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 3 @ 618 updates, score 37.84) (writing took 17.100803862325847 seconds)
2021-02-09 04:35:49 | INFO | fairseq_cli.train | end of epoch 3 (average epoch stats below)
2021-02-09 04:35:49 | INFO | train | epoch 003 | loss 2.54 | nll_loss 0.728 | ppl 1.66 | wps 12423.2 | ups 3.34 | wpb 3719.9 | bsz 451.8 | num_updates 618 | lr 7.725e-06 | gnorm 1.347 | loss_scale 2 | train_wall 39 | wall 200
2021-02-09 04:35:49 | INFO | fairseq_cli.train | begin training epoch 3
2021-02-09 04:36:04 | INFO | train_inner | epoch 004:     82 / 208 loss=2.509, nll_loss=0.692, ppl=1.62, wps=8932.3, ups=2.4, wpb=3716.5, bsz=443.3, num_updates=700, lr=8.75e-06, gnorm=1.323, loss_scale=2, train_wall=19, wall=216
2021-02-09 04:36:23 | INFO | train_inner | epoch 004:    182 / 208 loss=2.418, nll_loss=0.592, ppl=1.51, wps=19830.1, ups=5.25, wpb=3774.4, bsz=462.3, num_updates=800, lr=1e-05, gnorm=1.064, loss_scale=2, train_wall=19, wall=235
2021-02-09 04:36:28 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:36:29 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:36:29 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:36:30 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:36:30 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:36:30 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-09 04:36:30 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:36:33 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well glucose is regulated. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-09 04:36:33 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:36:33 | INFO | valid | epoch 004 | valid on 'valid' subset | loss 3.634 | nll_loss 1.885 | ppl 3.69 | bleu 41.18 | wps 930 | wpb 1083 | bsz 37.8 | num_updates 826 | best_bleu 41.18
2021-02-09 04:36:33 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:36:52 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 4 @ 826 updates, score 41.18) (writing took 19.152553741820157 seconds)
2021-02-09 04:36:52 | INFO | fairseq_cli.train | end of epoch 4 (average epoch stats below)
2021-02-09 04:36:52 | INFO | train | epoch 004 | loss 2.459 | nll_loss 0.636 | ppl 1.55 | wps 12217.7 | ups 3.28 | wpb 3719.9 | bsz 451.8 | num_updates 826 | lr 1.0325e-05 | gnorm 1.245 | loss_scale 2 | train_wall 39 | wall 263
2021-02-09 04:36:52 | INFO | fairseq_cli.train | begin training epoch 4
2021-02-09 04:37:06 | INFO | train_inner | epoch 005:     74 / 208 loss=2.383, nll_loss=0.552, ppl=1.47, wps=8651.5, ups=2.34, wpb=3703.4, bsz=457.8, num_updates=900, lr=1.125e-05, gnorm=1.168, loss_scale=2, train_wall=19, wall=278
2021-02-09 04:37:25 | INFO | train_inner | epoch 005:    174 / 208 loss=2.445, nll_loss=0.621, ppl=1.54, wps=19496.9, ups=5.3, wpb=3679.8, bsz=439.2, num_updates=1000, lr=1.25e-05, gnorm=1.251, loss_scale=2, train_wall=19, wall=296
2021-02-09 04:37:32 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:37:32 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:37:32 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:37:33 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:37:33 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:37:34 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-09 04:37:34 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:37:36 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well glucose is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-09 04:37:36 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:37:36 | INFO | valid | epoch 005 | valid on 'valid' subset | loss 3.652 | nll_loss 1.902 | ppl 3.74 | bleu 41.07 | wps 941.2 | wpb 1083 | bsz 37.8 | num_updates 1034 | best_bleu 41.18
2021-02-09 04:37:36 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:37:42 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_last.pt (epoch 5 @ 1034 updates, score 41.07) (writing took 5.579343692399561 seconds)
2021-02-09 04:37:42 | INFO | fairseq_cli.train | end of epoch 5 (average epoch stats below)
2021-02-09 04:37:42 | INFO | train | epoch 005 | loss 2.392 | nll_loss 0.561 | ppl 1.48 | wps 15549.2 | ups 4.18 | wpb 3719.9 | bsz 451.8 | num_updates 1034 | lr 1.2925e-05 | gnorm 1.118 | loss_scale 2 | train_wall 39 | wall 313
2021-02-09 04:37:42 | INFO | fairseq_cli.train | begin training epoch 5
2021-02-09 04:37:54 | INFO | train_inner | epoch 006:     66 / 208 loss=2.341, nll_loss=0.504, ppl=1.42, wps=12674.3, ups=3.41, wpb=3711.4, bsz=449.4, num_updates=1100, lr=1.375e-05, gnorm=1.016, loss_scale=2, train_wall=19, wall=326
2021-02-09 04:38:13 | INFO | train_inner | epoch 006:    166 / 208 loss=2.31, nll_loss=0.47, ppl=1.38, wps=19561.7, ups=5.23, wpb=3741.4, bsz=446, num_updates=1200, lr=1.5e-05, gnorm=1.034, loss_scale=2, train_wall=19, wall=345
2021-02-09 04:38:21 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:38:22 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:38:22 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:38:23 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:38:23 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:38:24 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-09 04:38:24 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:38:26 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-09 04:38:26 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:38:26 | INFO | valid | epoch 006 | valid on 'valid' subset | loss 3.636 | nll_loss 1.885 | ppl 3.69 | bleu 41.71 | wps 895.8 | wpb 1083 | bsz 37.8 | num_updates 1242 | best_bleu 41.71
2021-02-09 04:38:26 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:38:44 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 6 @ 1242 updates, score 41.71) (writing took 18.07931992597878 seconds)
2021-02-09 04:38:44 | INFO | fairseq_cli.train | end of epoch 6 (average epoch stats below)
2021-02-09 04:38:44 | INFO | train | epoch 006 | loss 2.336 | nll_loss 0.499 | ppl 1.41 | wps 12379.2 | ups 3.33 | wpb 3719.9 | bsz 451.8 | num_updates 1242 | lr 1.5525e-05 | gnorm 1.066 | loss_scale 2 | train_wall 39 | wall 376
2021-02-09 04:38:44 | INFO | fairseq_cli.train | begin training epoch 6
2021-02-09 04:38:55 | INFO | train_inner | epoch 007:     58 / 208 loss=2.344, nll_loss=0.507, ppl=1.42, wps=8777.6, ups=2.39, wpb=3674.6, bsz=447.7, num_updates=1300, lr=1.625e-05, gnorm=1.115, loss_scale=2, train_wall=19, wall=387
2021-02-09 04:39:14 | INFO | train_inner | epoch 007:    158 / 208 loss=2.293, nll_loss=0.45, ppl=1.37, wps=19558.1, ups=5.28, wpb=3706.7, bsz=447.8, num_updates=1400, lr=1.75e-05, gnorm=1.053, loss_scale=2, train_wall=19, wall=406
2021-02-09 04:39:24 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:39:24 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:39:24 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:39:25 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:39:25 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:39:26 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-09 04:39:26 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:39:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body cannot process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is controlled. What benefit has Actrapid shown in these trials? concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-09 04:39:28 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:39:28 | INFO | valid | epoch 007 | valid on 'valid' subset | loss 3.685 | nll_loss 1.932 | ppl 3.82 | bleu 43.13 | wps 909.6 | wpb 1083 | bsz 37.8 | num_updates 1450 | best_bleu 43.13
2021-02-09 04:39:28 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:39:47 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 7 @ 1450 updates, score 43.13) (writing took 18.185215960256755 seconds)
2021-02-09 04:39:47 | INFO | fairseq_cli.train | end of epoch 7 (average epoch stats below)
2021-02-09 04:39:47 | INFO | train | epoch 007 | loss 2.288 | nll_loss 0.445 | ppl 1.36 | wps 12391.3 | ups 3.33 | wpb 3719.9 | bsz 451.8 | num_updates 1450 | lr 1.8125e-05 | gnorm 1.01 | loss_scale 2 | train_wall 39 | wall 438
2021-02-09 04:39:47 | INFO | fairseq_cli.train | begin training epoch 7
2021-02-09 04:39:56 | INFO | train_inner | epoch 008:     50 / 208 loss=2.228, nll_loss=0.381, ppl=1.3, wps=9050.9, ups=2.38, wpb=3804, bsz=477.6, num_updates=1500, lr=1.875e-05, gnorm=0.791, loss_scale=2, train_wall=19, wall=448
2021-02-09 04:40:15 | INFO | train_inner | epoch 008:    150 / 208 loss=2.266, nll_loss=0.421, ppl=1.34, wps=19681.3, ups=5.28, wpb=3729.4, bsz=447.6, num_updates=1600, lr=2e-05, gnorm=1.036, loss_scale=2, train_wall=19, wall=467
2021-02-09 04:40:26 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:40:27 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-09 04:40:27 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:40:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:40:28 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:40:29 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-09 04:40:29 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:40:31 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapid to a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is controlled. What benefit has Actrapid shown in these trials? HbA1c concentrations have remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-09 04:40:31 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:40:31 | INFO | valid | epoch 008 | valid on 'valid' subset | loss 3.737 | nll_loss 1.998 | ppl 4 | bleu 42.47 | wps 927.3 | wpb 1083 | bsz 37.8 | num_updates 1658 | best_bleu 43.13
2021-02-09 04:40:31 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:40:37 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_last.pt (epoch 8 @ 1658 updates, score 42.47) (writing took 5.912781343795359 seconds)
2021-02-09 04:40:37 | INFO | fairseq_cli.train | end of epoch 8 (average epoch stats below)
2021-02-09 04:40:37 | INFO | train | epoch 008 | loss 2.247 | nll_loss 0.399 | ppl 1.32 | wps 15418.5 | ups 4.14 | wpb 3719.9 | bsz 451.8 | num_updates 1658 | lr 2.0725e-05 | gnorm 0.923 | loss_scale 2 | train_wall 39 | wall 488
2021-02-09 04:40:37 | INFO | fairseq_cli.train | begin training epoch 8
2021-02-09 04:40:45 | INFO | train_inner | epoch 009:     42 / 208 loss=2.221, nll_loss=0.369, ppl=1.29, wps=12486.1, ups=3.37, wpb=3705.9, bsz=453.2, num_updates=1700, lr=2.125e-05, gnorm=0.837, loss_scale=2, train_wall=19, wall=496
2021-02-09 04:41:04 | INFO | train_inner | epoch 009:    142 / 208 loss=2.231, nll_loss=0.38, ppl=1.3, wps=19302.8, ups=5.26, wpb=3672.9, bsz=441.6, num_updates=1800, lr=2.25e-05, gnorm=0.96, loss_scale=2, train_wall=19, wall=515
2021-02-09 04:41:17 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:41:17 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-09 04:41:17 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:41:18 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-09 04:41:18 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:41:19 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-09 04:41:19 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:41:21 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). Actrapide was compared with a human insulin analogue (insulin Aspart) by measuring levels in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is controlled. What benefit has actrapid shown in these trials? HbA1c concentrations have remained relatively stable during 6 months of treatment with Actrapid.
2021-02-09 04:41:21 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:41:21 | INFO | valid | epoch 009 | valid on 'valid' subset | loss 3.811 | nll_loss 2.087 | ppl 4.25 | bleu 42.65 | wps 966.9 | wpb 1083 | bsz 37.8 | num_updates 1866 | best_bleu 43.13
2021-02-09 04:41:21 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:41:26 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_last.pt (epoch 9 @ 1866 updates, score 42.65) (writing took 5.601873924955726 seconds)
2021-02-09 04:41:26 | INFO | fairseq_cli.train | end of epoch 9 (average epoch stats below)
2021-02-09 04:41:26 | INFO | train | epoch 009 | loss 2.213 | nll_loss 0.361 | ppl 1.28 | wps 15558 | ups 4.18 | wpb 3719.9 | bsz 451.8 | num_updates 1866 | lr 2.3325e-05 | gnorm 0.868 | loss_scale 2 | train_wall 39 | wall 538
2021-02-09 04:41:26 | INFO | fairseq_cli.train | begin training epoch 9
2021-02-09 04:41:33 | INFO | train_inner | epoch 010:     34 / 208 loss=2.203, nll_loss=0.35, ppl=1.27, wps=12718.1, ups=3.43, wpb=3707.8, bsz=452.8, num_updates=1900, lr=2.375e-05, gnorm=0.806, loss_scale=2, train_wall=19, wall=545
2021-02-09 04:41:52 | INFO | train_inner | epoch 010:    134 / 208 loss=2.164, nll_loss=0.307, ppl=1.24, wps=19345.8, ups=5.16, wpb=3749.9, bsz=455, num_updates=2000, lr=2.5e-05, gnorm=0.697, loss_scale=2, train_wall=19, wall=564
2021-02-09 04:42:07 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-09 04:42:07 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-09 04:42:07 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-09 04:42:08 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin products.
2021-02-09 04:42:08 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-09 04:42:09 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-09 04:42:09 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-09 04:42:11 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). Actrapide was compared with a human insulin analogue (insulin Aspart) by measuring levels in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is controlled. What benefit has Actrapid shown in these trials? HbA1c concentrations have remained relatively stable during 6 months of treatment with Actrapid.
2021-02-09 04:42:11 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-09 04:42:11 | INFO | valid | epoch 010 | valid on 'valid' subset | loss 3.811 | nll_loss 2.1 | ppl 4.29 | bleu 43.65 | wps 986.2 | wpb 1083 | bsz 37.8 | num_updates 2074 | best_bleu 43.65
2021-02-09 04:42:11 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-09 04:42:28 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_tp/checkpoint_best.pt (epoch 10 @ 2074 updates, score 43.65) (writing took 17.018968644551933 seconds)
2021-02-09 04:42:28 | INFO | fairseq_cli.train | end of epoch 10 (average epoch stats below)
2021-02-09 04:42:28 | INFO | train | epoch 010 | loss 2.186 | nll_loss 0.332 | ppl 1.26 | wps 12571.2 | ups 3.38 | wpb 3719.9 | bsz 451.8 | num_updates 2074 | lr 2.5925e-05 | gnorm 0.799 | loss_scale 2 | train_wall 40 | wall 599
2021-02-09 04:42:28 | INFO | fairseq_cli.train | done training in 590.4 seconds


###############################################################################
Peregrine Cluster
Job 17889397 for user 's3475743'
Finished at: Tue Feb  9 04:42:32 CET 2021

Job details:
============

Job ID              : 17889397
Name                : EMEA_p_4_tp
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu24
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-02-09T03:17:36
Start               : 2021-02-09T04:31:41
End                 : 2021-02-09T04:42:32
Reserved walltime   : 23:55:00
Used walltime       : 00:10:51
Used CPU time       : 00:11:08 (efficiency:  8.55%)
% User (Computation): 61.90%
% System (I/O)      : 38.10%
Mem reserved        : 32G/node
Max Mem used        : 5.60G (pg-gpu24)
Max Disk Write      : 51.20K (pg-gpu24)
Max Disk Read       : 2.22M (pg-gpu24)
Average GPU usage   : 79.2% (pg-gpu24)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
